Bioextrax once again reported figures close to our estimates in its recent Q3 report. Both revenues and costs were slightly lower than our expectations, and as a result, EBITDA came in MSEK 0.1 above our expectations, at MSEK -4.2. A fully secured rights issue of MSEK 13.3 will fund bioextrax through most of 2026, and we expect a new round of financing in Q4. News during the quarter have prompted us to make changes in our model. We have lowered our revenue forecasts in the short term, with long-term revenues being less affected.
Read the full report here.